Back to Hematology
Hematologyv1998Evidence-Based

MASCC Risk Index for Febrile Neutropenia

Identifies febrile neutropenia patients at low risk for poor outcome including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications. Developed by Multinational Association for Supportive Care in Cancer (MASCC) to guide outpatient vs inpatient management decisions.

Clinical Input Parameters

years
Range: 18 — 100 years
Clinical Assessment
Awaiting Parameters
mascc risk index
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The MASCC Risk Index for Febrile Neutropenia is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

MASCC Risk Index = Burden of illness points + Hypotension points + COPD points + Cancer type points + Dehydration points + Fever onset status points + Age points. Maximum score 26 points. Score ≥21 indicates low risk for complications.

Clinical Pearls & Practice Notes

  • Developed from 756 patients in derivation cohort and validated in 383 patients
  • Positive predictive value of 91% for low-risk classification in original validation
  • Specificity 68% and sensitivity 71% in original validation study
  • External validation studies show PPV range 83-98% with sensitivity 59-95%
  • Performance may be lower in patients with hematologic malignancies
  • Does not incorporate neutrophil count <0.1 x10⁹/L or expected prolonged neutropenia ≥7 days
  • Only applies to adult patients (≥18 years)
  • Not recommended for acute leukemia or stem cell transplant patients
  • Clinical judgment should always override the score when indicated
  • Endorsed by Infectious Diseases Society of America (IDSA) guidelines
  • Outpatient management requires reliable access to medical care and follow-up
  • Score designed to identify patients suitable for less intensive management strategies
  • Regular reassessment needed if clinical condition changes during treatment

Evidence & Literature Citations

  1. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 Aug;18(16):3038-51. doi: 10.1200/JCO.2000.18.16.3038.
  2. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.
  3. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004 Aug;12(8):555-60. doi: 10.1007/s00520-004-0614-5.

Score Interpretation Ranges

High Risk0 – 20 pts

High risk for complications

Low Risk21 – 26 pts

Low risk for complications

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.